EICHORCondition: Lymphoma, B-Cell · Lymphoma, T-Cell · Sponsor: Step Pharma, SAS
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
This description comes directly from the study's public registry record.
Maureen Higgins · +33 1 86 26 43 56 · STP938-101@step-ph.com
Duc Tran · +33 1 86 26 43 56 · STP938-101@step-ph.com
Always discuss trial participation with your own doctor first.
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Sarasota, Florida, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| Hôpital Saint-Louis | Paris, Paris, France | Recruiting |
| The Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| CHU de Nantes | Nantes, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| University Hospitals of Leicester NHS Trust | Leicester, United Kingdom | Recruiting |
| Imperial College / Clinical Trials Unit, Hammersmith Hospital | London, United Kingdom | Recruiting |
| The Christie | Manchester, United Kingdom | Recruiting |
| Nottingham City Hospital | Nottingham, United Kingdom | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05463263